Just suppose if a tablet is prepared in such a way that a person can get the applicable quality of medicine and best quality of packing, so AZITHROMYCIN 500 TABLETS is a high strength of medicine delivered for several needs. It manufactured according to the quality standards of the pharmacy with an active 500 mg of Azithromycin in a single oral dose. But have you ever thought of the manufacture of this high strength tablet? It is a chain of active-ingredient packing, excipient selection, powder handling, and advanced manufacturing conditions. This product could be added to your PCD Pharma Franchise range.
INITIATING AZITHROMYCIN 500 TABLETS MANUFACTURING PHASE Step 1-Azithromycin In a 500 mg tablet, the active pharmaceutical ingredient is king. Blend uniformity and compression properties must be controlled tightly. What's the best way to achieve this? First, you must select the appropriate excipients, including diluents, binders, disintegrants, glidants, and lubricants, evaluating each for impurities, particle size, and moisture, as well as its potential to interact with Azithromycin.
Accurate dosing is important, so each batch has the same formulary. With a combination of weighings, weight verification, and written instructions, our formula is thorough from tablet size, to breakability, strength, disintegration, and dissolution profiles - the perfect recipe.
Prior to these tablets appearing in the world, Azithromycin and its fellow API wrestle through the difficult powder processing steps to generate a uniform, compressible blend. Direct compression or granulation both bring their complications to bear on everything from powder flow to density. How do you achieve consistent quality? Particle-size distribution, amount of binder, drying conditions…the devil is definitely in the details.
In direct compression, flowability and compressability of the blend are critical. The blend is composed by a process variable so the active has an even distribution, after which sampling before compression ensures blend uniformity.
The blend is then compressed to form AZITHROMYCIN 500 TABLETS, tablets having characteristics as specified below: Compression force, turret speed and condition of tooling directly affects the weight, thickness and hardness of the tablets. In-process controls at pre-determined intervals detect deviations of these parameters.
Size of the tablets versus disintegration and dissolution. Excessive compression may alter the porosity and the release characteristics of the final product, while poor compression may lead to fragile tablets. In the case of the film coating, conditions are checked to control the coating weight and the surface, as well as the coating conditions (spray rate and drying).
The AZITHROMYCIN 500 TABLETS are subjected to complete analytical testing and physical inspection to confirm they conform to product specification. Identiï¬ cation and assay test ascertain the presence of, and the quantity of Azithromycin in the product, as conformed by testing. Uniformity of dosage units test conform to specifications.
Dissolution tests ensures the release performance are tested in standardized conditions, and more weight checks, disintegration, hardness, friability and impurities are also considered. All tests are supported by suitable sampling, calibrated equipment and validated methods, and the data are carefully evaluated against set specifications prior to batch release.
Stability of the AZITHROMYCIN 500 TABLETS studies are conducted to verify if the AZITHROMYCIN 500 TABLETS maintain effectiveness during the period they are authorized for use. Such studies include the test of assay, dissolution, appearance and physical characteristics. Packaging materials such as moisture-proof, environment-proof or cushion-packaging are essential for the stability of AZITHROMYCIN 500 TABLETS.
The packaging system should protect the product during storage and transport, and facilitate its identification and traceability. The label should specify the product name, strength, batch number, expiration date, and legal requirements.
AZITHROMYCIN 500 TABLETS Easy integration in a structured pharmaceutical portfolio, with focus on formulation control, blend uniformity, compression uniformity, and so on. For firms in the process of building up a PCD Pharma Franchise, adherence to consistent specifications and documented procedures will facilitate the transition from production to quality assurance and distribution. Consistent documentation will permit traceability and reproducibility of the processes.
The process begins with the selection of raw materials and concludes with finished goods, packaging and release. The AZITHROMYCIN 500 TABLETS development process from formulation trials, blend evaluation, and compression development through to product testing, stability testing and packing. In every case the process is tightly managed to produce quality and consistency.
Azithromycin 500 Tablets with controlled formulation, blend uniformity, compression, dissolution, quality testing, stability and packaging.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech